Legislative Agenda

Through our legislative agenda we are advancing brain tumor research, facilitating the development of treatments, and fighting for a better quality of life for patients.

  1. Federal Research Funding

    We're urging Congress to maintain its historic bipartisan commitment to the fight against cancer, including brain tumors, by increasing appropriations for the National Institutes of Health (NIH) and the National Cancer Institute (NCI).

    Read more
  2. Clinical Trial Endpoints Initiative

    While brain tumor patients want therapies that increase their survival, they also want improvement in their quality of life. This initiative aims to establish with the FDA accepted clinical trial goals and guidance that will incentivize the pharmaceutical industry to develop and deliver therapies that achieve better outcomes for the brain tumor community.

    Read more
  3. Oral Chemotherapy Parity

    We support legislation that would prohibit health insurers from charging patients that are prescribed oral chemotherapy such as temozolomide more per month than they do those given intravenous chemotherapy. We ask Congress to support the Cancer Drug Coverage Parity Act and the Cancer Treatment Parity Act.

    Read more
  4. Health Care Reform Implementation

    We support the implementation of the Affordable Care Act (ACA) in a manner that ensures affordable access to adequate coverage of essential health care services that brain tumor patients need.

    Read more
  5. Incentives for Improving Pediatric Brain Tumor Clinical Trials

    We are investigating barriers to brain tumor researchers acquiring potentially therapeutic compounds for pediatric clinical trials. We will examine what public policy incentives and regulations exist and may need to be established in order to increase access to compounds by researchers.

    Read more
  6. Issue Archive

    Together, with partner organizations and dedicated advocates, we've worked over the years to address critical legislative issues affecting this community. Learn more about past issues.

    Read more